Browse

Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Cited 5 time in Web of Science Cited 6 time in Scopus
Authors
Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog
Issue Date
2019-09
Citation
Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566
Keywords
OsimertinibNSCLCEGFR exon 20 insertionResistance
Abstract
Introduction: NSCLC with EGFR exon 20 insertion mutations is the third most common type of EGFR-mutant NSCLC and is resistant to EGFR tyrosine kinase inhibitors (TKIs). This study was conducted to evaluate the efficacies of first-to third-generation EGFR TKIs against NSCLC cells harboring EGFR exon 20 insertion mutations. Methods: We developed seven EGFR exon 20 insertion-mutant Ba/F3 models and one patient-derived NSCLC (SNU-3173) of subtypes A763insFQEA, V769insASV, D770insSVD, D770insNPG, P772insPR, H773insH, H773insNPH, and H773insAH. Cell viability assays, immunoblotting, and N-ethyl-N-nitrosourea mutagenesis screenings were performed. EGFR exon 20 insertion-mutant structures and couplings with osimertinib, a third-generation EGFR TKI, were modeled and compared. Results: EGFR exon 20 insertion-mutant NSCLC cells, excluding EGFR A763insFQEA, were resistant to first-generation EGFR TKIs (concentration that inhibits 50% [IC50], 1.1 +/- 0.067 to 5.4 +/- 0.115 mu M). Mutants were sensitive to second-generation EGFR TKIs (IC50, 0.02 +/- 0.0002 to 161.8 +/- 18.7nM), except EGFR H773insH (IC50, 46.3 +/- 8.0 to 352.5 +/- 22.7nM). The IC50 ratios for mutant to wild-type cells were higher than those for third-generation EGFR TKIs. Third-generation EGFR TKI osimertinib was highly potent against EGFR exon 20 insertion-mutant cells (IC50, 14.7-62.7 nM), including EGFR H773insH, and spared wild-type EGFR cells. N-ethyl-N-nitrosourea mutagenesis screening of EGFR exon 20 insertion-mutant Ba/F3 cells showed various second sites for EGFR mutations, mostly at exons 20 and 21, including E762K, P794S, and G796D. In addition, osimertinib-resistant cells were established by stepwise exposure to osimertinib and harbored EGFR E762K mutation. Conclusions: Osimertinib is active against EGFR exon 20 insertion- mutant NSCLC and flexibly binds within drug-binding pockets in preclinical models. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
ISSN
1556-0864
URI
https://hdl.handle.net/10371/171816
DOI
https://doi.org/10.1016/j.jtho.2019.05.006
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse